ENVISION Phase 3 Study

Posted by & filed under .

Evaluating the effect of givosiran (ALN-AS1) on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP). Trial Status: Enrolling Interested in learning more? Please email us at clinicaltrials@alnylam.com For… read more //